Worst performing, not sure, but certainly bad performing when...

Worst performing, not sure, but certainly bad performing when the sp is the only criteria.

Definitely fantastic platforms and progress made but the change in interest policies that caused a market change from potential to income and Hopper's more than questionable funding strategy got CHM to almost ZERO value.

New way of presenting, bits from IMU ( dose escalation charts ) and some new unique CHM features. Unfortunately the market gives a rat's ass atm about CDH 17 or CLTX, prefers the not so efficient ALA management over the world leading CHM Team, assets and data.

If CDH 17 is really one of the best things since sliced bread then even SHEMARA will find positive words for CHM.

Great presentation, just miss the "cash at hand " figure but that would be estimated sub $10m and soon be changed by the upcoming capital restructure similar to RAD.

GLTA